Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
19030	Atezolizumab	Tecentriq®	In combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	NCPE Assessment Process Complete	24th September 2020
20060	Atezolizumab in combination with bevacizumab	Tecentriq®	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.	NCPE Assessment Process Complete	8th May 2023
20039	Atezolizumab	Tecentriq®	Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%.	Rapid Review Complete	23rd September 2020
21009	Atidarsagene autotemcel	Libmeldy®	For the treatment of metachromatic leukodystrophy characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity, in children with late infantile or early juvenile forms without clinical manifestations of the disease, and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.	NCPE Assessment Process Complete	30th September 2022
21005	Autologous anti-CD19-transduced CD3+ cells	Tecartus®	For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.	Pre submission consultation scheduled	2nd June 2023
22009	Avacopan	Tavneos®	In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic  polyangiitis.	NCPE assessment ongoing	28th April 2023
-	Avanafil	Spedra®	For the treatment of erectile dysfunction in adult men.	Rapid Review Complete	2nd May 2014
20006	Avatrombopag	Doptelet®	For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.	Rapid Review Complete	2nd April 2020
20058	Avatrombopag	Doptelet®	For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Rapid Review Complete	15th February 2021
-	Avelumab	Bavencio®	For the treatment of adults with metastatic Merkel Cell Carcinoma.	NCPE Assessment Process Complete	9th October 2018
19046	Avelumab	Bavencio®	Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.	NCPE Assessment Process Complete	23rd June 2021
21001	Avelumab	Bavencio®	As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy.	NCPE Assessment Process Complete	22nd December 2021
-	Axicabtagene Ciloleucel	Yescarta®	For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.	NCPE Assessment Process Complete	25th February 2020
22066	Axicabtagene ciloleucel	Yescarta®	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Awaiting full HTA submission from Applicant	21st March 2023
-	Axitinib	Inlyta®	For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine	Rapid Review Complete	20th November 2012
-	Azelastine hydrochloride and fluticasone propionate (nasal spray)	Dymista®	For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Rapid Review Complete	28th February 2013
-	Azilsartan	Edarbi®	For the treatment of essential hypertension in adults.	Rapid Review Complete	11th January 2012
21050	Baricitinib	Olumiant®	Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.	Rapid Review complete	16th December 2021
-	Baricitinib	Olumiant®	Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.	Rapid Review complete	13th July 2017
20056	Baricitinib	Olumiant®	Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.	Rapid Review complete	28th January 2021
-	Bazedoxifene	Conbriza®	Treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.	Rapid Review complete	2nd January 2011
-	Bedaquiline	Sirturo®	For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Rapid Review complete	20th February 2015
-	Belatacept	Nulojix®	In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.	Rapid Review complete	23rd January 2012
-	Belimumab	Benlysta®	As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.	Rapid Review complete	31st August 2011
23021	Belimumab	Benlysta®	Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.	Rapid Review Complete	16th May 2023
23022	Belimumab	Benlysta®	Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.	Rapid Review Complete	29th May 2023
20026a	Bempedoic acid	Nilemdo®	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, OR Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated	NCPE Assessment process complete	16th November 2021
20026b	Bempedoic acid/Ezetimibe	Nustendi®	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet (a) in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (b) alone in patients who are either statin – intolerant or for whom a statin is contraindicated and are unable to reach LDL-C goals with ezetimibe alone and (c) in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.	NCPE Assessment Process Complete	16th November 2021
-	Bendamustine	Levact®	Treatment of Chronic Lymphocytic Leukaemia (CLL)	NCPE Assessment Process Complete	20th November 2012
-	Benralizumab	Fasenra®	As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.	Rapid Review complete	14th February 2018
20018	Benralizumab	Fasenra®	As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.	Rapid Review complete	28th April 2020
22031	Berotralstat	Orladeyo®	Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older	Awaiting full HTA submission from Applicant	28th March 2023
-	Bezlotoxumab	Zinplava®	Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.	Rapid Review complete	14th June 2017
-	Bictegravir/emtricitabine/tenofovir alafenamide	Biktarvy®	Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.	Rapid Review complete	7th June 2018
-	Bilastine	Drynol®	Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.	Rapid Review complete	23rd March 2011
21052	Bimekizumab	Bimzelx®	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Rapid Review complete	7th January 2022
-	Blinatumomab	Blincyto®	Treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia.	NCPE Assessment Process Complete	16th April 2018
-	Blinatumomab	Blincyto®	As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL)  in first or second complete remission with minimal residual disease greater than or equal to 0.1%.	Rapid Review complete	23rd September 2019
-	Blinatumomab	Blincyto®	Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation	Rapid Review complete	30th January 2019
21031	Blinatumomab	Blincyto®	Treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy.	Rapid Review complete	3rd August 2021
-	Boceprevir	Victrelis®	As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.	NCPE Assessment Process Complete	17th January 2012
-	Bosentan	Tracleer®	Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.	Rapid Review complete	8th July 2014
-	Bosutinib	Bosulif®	Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	Rapid Review complete	25th September 2013
-	Brentuximab vedotin	Adcetris®	Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.	NCPE Assessment Process Complete	11th April 2014
-	Brentuximab vedotin	Adcetris®	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension).	Rapid Review complete	6th March 2018
19058	Brentuximab vedotin	Adcetris®	Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.	NCPE Assessment Process Complete	22nd October 2021
21010	Brentuximab vedotin	Adcetris®	In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).	Rapid Review complete	23rd April 2021
-	Brigatinib	Alunbrig®	As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.	Rapid Review complete	11th December 2018
20031	Brigatinib	Alunbrig®	As monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK-inhibitor.	Rapid Review complete	6th August 2020
-	Brimonidine	Mirvaso®	Treatment of facial erythema of rosacea in adult patients.	Rapid Review complete	7th May 2014